PDCD1 and melanoma: Progression-free survival at 12 months was 47.7% with relatlimab-nivolumab as compared with 36.0% with nivolumab.The inhibition of two immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to progression-free survival than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma [11].